Search Within

Ping Chi

Formats
  1. Journal Article (91)
  2. Meeting Abstract (81)
  3. Review (2)
  4. Miscellaneous (1)
Groups
  1. Department of Medicine (175)
  2. GSK Faculty (175)
  3. Human Oncology and Pathogenesis Program (175)
  4. Sarcoma Service (175)
  5. Solid Tumor Oncology Division (175)
  6. Tow Center for Developmental Oncology (TCDO) (175)

More Groups

People
  1. William Tap (70)
  2. Cristina Antonescu (67)
  3. Sandra D'Angelo (60)
  4. Mrinal Gounder (58)
  5. Mary Keohan (57)
  6. Mark Dickson (56)

More People

Years
  1. 2025 (6)
  2. 2024 (18)
  3. 2023 (19)
  4. 2022 (30)
  5. 2021 (20)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (18)
  3. Annals of Oncology (14)
  4. Cancer Research (11)
  5. Genes Chromosomes and Cancer (5)
  6. JCO Precision Oncology (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (42)
  2. American Association for Cancer Research (35)
  3. Oxford University Press (20)
  4. Nature Publishing Group (16)
  5. Elsevier Inc. (8)
  6. Cell Press (6)

More Publishers

Results (175)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeted CRISPR-Knockout (KO) screening to identify FOXF1 regulators and therapeutic strategies in gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Tomas, F.; Cho, W. H.; Li, D.; Callychurn, V. R.; Wang, N.; Yu, C.; Chi, P.
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • MEK inhibitors lead to PDGFR pathway upregulation and sensitize tumors to RAF dimer inhibitors in NF1-deficient malignant peripheral nerve sheath tumor
    Journal Article

    Miranda-Román, M. A.; Lee, C. J.; Fishinevich, E.; Ran, L.; Patel, A. J.; Yan, J.; Khudoynazarova, M. N.; Warda, S.; Pachai, M. R.; Chen, Y.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • The INSIGHT study: A randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations
    Journal Article

    George, S.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations
    Meeting Abstract

    Zalcberg, J. R.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Reichmann, W.; Sprott, K.; Cox, P.; Sherman, M. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Li, J.; Chi, P.; Kang, Y. K.; Cao, H.; George, S.; Zhang, J.; Zhang, J.; Hu, K.; Zhang, L. J.; Xu, Y. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study
    Meeting Abstract

    Chandana, S. R.; Shepard, D. R.; Mehnert, J. M.; Chi, P.; Trent, J. C.; Psoinos, C. M.; Zhou, B.; Black, V.; Viswanathan, L.; Gozo, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Bradic, M.; Desir, R.; Kelly, C. M.; Movva, S.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors
    Meeting Abstract

    Kelly, C. M.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; Clark, C.; Counihan, O.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • NF1-driven rhabdomyosarcoma phenotypes: A comparative clinical and molecular study of NF1-mutant rhabdomyosarcoma and NF1-associated malignant triton tumor
    Journal Article

    de Traux de Wardin, H.; Dermawan, J. K.; Vanoli, F.; Jiang, S. C.; Singer, S.; Chi, P.; Tap, W.; Wexler, L. H.; Antonescu, C. R.
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save